CoQ10vsEmoxypine (Mexidol)

CoQ10 (ubiquinone/ubiquinol) shuttles electrons between Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) and Complex III (cytochrome bc1 complex) of the mitochondrial electron transport chain. This is the fundamental process of oxidative phosphorylation—electrons flow through the chain to Complex IV, driving proton pumping and ATP synthesis via Complex V (ATP synthase). Without adequate CoQ10, the chain bottlenecks at the CoQ pool and energy production drops, particularly in high-metabolic tissues like neurons. As a lipid-soluble antioxidant, CoQ10 (in its reduced ubiquinol form) protects mitochondrial membranes from lipid peroxidation by terminating free radical chain reactions. It also regenerates vitamin E (tocopherol) from its radical form, amplifying antioxidant capacity. Brain CoQ10 levels decline with age.

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) has a 3-hydroxypyridine structure similar to vitamin B6 (pyridoxine). It is one of the most potent inhibitors of lipid peroxidation in brain tissue — it scavenges hydroxyl radicals and peroxyl radicals, inhibits Fe2+-induced lipid peroxidation, and may chelate transition metals. It modulates the GABA-benzodiazepine receptor complex (GABA-A), enhancing GABAergic transmission through positive allosteric modulation — possibly at a site distinct from the classical benzodiazepine binding site, explaining the lack of sedation and tolerance. It improves mitochondrial function (Complex I protection, membrane stabilization), stabilizes cell membranes (reducing fluidity changes during oxidative stress), and enhances cerebral microcirculation (possibly via nitric oxide or prostaglandin modulation). The anxiolytic mechanism may involve partial agonism or different subunit selectivity.